SALT LAKE CITY, Aug. 25, 2020 /PRNewswire/
-- Co-Diagnostics, Inc. (Nasdaq: CODX), a
molecular diagnostics company with a unique, patented platform for
the development of diagnostic tests, announced today that Company
CEO Dwight Egan will be discussing
the Company's significant growth, profitability, and future
objectives at H.C. Wainwright's 22nd Annual Global
Investment Conference on Monday, September
14th at 10:00
ET.
Co-Diagnostics continues to achieve substantial growth, driven
by domestic and international sales of its high-throughput Logix
Smart COVID-19 test, as Q2 2020 revenue increased 1,503% over Q1
2020 to over $24 million, and
earnings surged from a loss in the previous quarter to over
$12 million. Mr. Egan will provide a
recap of the Company's financial, scientific, and regulatory
accomplishments in the context of the ongoing global coronavirus
health crisis, as well as outline how Co-Diagnostics expects to
remain a leader in cutting-edge molecular diagnostics
solutions.
"Co-Diagnostics has been at the forefront of the battle against
the coronavirus since January, and our innovative design platform
and patented CoPrimer™ technology have allowed us to stand out and
enabled our rapid rise to impressive sales and profitability,"
remarked Mr. Egan. "We believe both our outstanding financial and
scientific achievements, as well as our regulatory authorizations
by the US FDA, India, European
Community and others, and our expanded distributor network covering
nearly 50 countries and over 25 states have all positioned the
Company for extraordinary future growth."
Participants in the September
14-16 conference, which will be held virtually, include
public companies, industry executives, business development
executives, institutional investors, and more. Co-Diagnostics
invites participating fund managers and other investing
institutions to schedule one-on-one meetings with the Company,
which may be booked via H.C. Wainwright after registering to
attend.
Additional details will be posted to the Company's Events and
Presentation page closer to the date of the conference. More
information about the conference may be found here.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets a
state-of-the-art diagnostics technology. The Company's technology
is utilized for tests that are designed using the detection and/or
analysis of nucleic acid molecules (DNA or RNA). The Company also
uses its proprietary technology to design specific tests to locate
genetic markers for use in industries other than infectious disease
and license the use of those tests to specific customers.
Forward-Looking Statements:
This press release
contains forward-looking statements. Forward-looking statements can
be identified by words such as "believes," "expects," "estimates,"
"intends," "may," "plans," "will" and similar expressions, or the
negative of these words. Such forward-looking statements are based
on facts and conditions as they exist at the time such statements
are made and predictions as to future facts and conditions.
Forward-looking statements in this release include statements
regarding the (i) use of funding proceeds, (ii) expansion of
product distribution, (iii) acceleration of initiatives in liquid
biopsy and SNP detection, (iv) use of the Company's liquid biopsy
tests by laboratories, (v) capital resources and runway needed to
advance the Company's products and markets, (vi) increased sales in
the near-term, (vii) flexibility in managing the Company's balance
sheet, (viii) anticipation of business expansion, and (ix) benefits
in research and worldwide accessibility of the CoPrimer technology
and its cost-saving and scientific advantages. Forward-looking
statements are subject to inherent uncertainties, risks and changes
in circumstances. Actual results may differ materially from
those contemplated or anticipated by such forward-looking
statements. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/co-diagnostics-inc-to-discuss-recent-company-growth-and-upcoming-expansion-plans-at-hc-wainwright-global-investment-conference-301117558.html
SOURCE Co-Diagnostics